Icon Clinical Research - New York City, New York 10017

Icon Clinical Research is categorized under Research and Development Laboratories in New York City, NY .

Business Name: Icon Clinical Research
Contact Person: Ray Rivera
Address: 140 East 45th St Floor 11, New York City, New York 10017
Phone Number: (212) 682-2666
Website Address: iconplc.com
Annual Revenue (USD): $1.000.000 to $2.499.999
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Research and Development Laboratories
SIC Code: 8731
NAICS Code: 6214930
Share This Business:
Related Businesses: Synthesis Energy Systems Inc - New York City, NY 10017
Support Technologies Inc - New York City, NY 10017
Insight Catastrophe Group LLC - New York City, NY 10017
Tti Technologies International Inc - New York City, NY 10017
Cosmetic Research Development - New York City, NY 10017
China Security & Survelliance Technology Inc - New York City, NY 10017
Vhayu Technologies - New York City, NY 10017
I D G Technology Networks - New York City, NY 10017
Technology Search International - New York City, NY 10017
Insight Catasrophe Group - New York City, NY 10017
Red Stone Information Technology - New York City, NY 10017

The company Icon Clinical Research provides B2B services in the form of Research and Development Laboratories from its single location in New York. 1 to 4 employees work for Icon Clinical Research, and the business now earns $1.000.000 to $2.499.999 per annum.

Icon Clinical Research was launched in 0 and is classified under SIC code and category 8731 , and NAICS number and grouping 6214930 . To contact Icon Clinical Research, please call Ray Rivera with the phone number (212) 682-2666 or visit its single location at 140 East 45th St Floor 11 in New York City, New York 10017.

The location of the single location can also be found using the coordinates 40.753163,-73.974309. Read more details about this business on the webpage iconplc.com or follow the company’s social media accounts, on Twitter and on Facebook.